Publicaciones en las que colabora con EDUARDO DÍAZ-RUBIO GARCÍA (85)

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

2022

  1. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

    Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210

  2. Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets

    Cancers, Vol. 14, Núm. 21

  3. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

    ESMO open, Vol. 6, Núm. 2, pp. 100062

2020

  1. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected

    Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116

2019

  1. Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials

    ESMO Open, Vol. 4, Núm. 6

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

2016

  1. C8-T1 radiculopathy due to an intradural extramedullary metastasis of a pancreatic neuroendocrine tumor: Case report and review of the literature

    Pancreas, Vol. 45, Núm. 5, pp. 772-779

  2. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable CT3-4 or N+ rectal cancer: Five-year disease-free survival results of a single-center series

    Clinical Colorectal Cancer, Vol. 15, Núm. 2, pp. 128-134

2015

  1. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours

    European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380

  2. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

    Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324

  3. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy

    Molecular Diagnosis and Therapy, Vol. 19, Núm. 6, pp. 397-408

  4. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

    Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541

2014

  1. Impact of cetuximab in current treatment of metastatic colorectal cancer

    Expert Opinion on Biological Therapy, Vol. 14, Núm. 3, pp. 387-399

  2. Role of cetuximab in first-line treatment of metastatic colorectal cancer

    World Journal of Gastroenterology, Vol. 20, Núm. 15, pp. 4208-4219

  3. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?

    World Journal of Gastroenterology, Vol. 20, Núm. 20, pp. 6092-6101

2013

  1. Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer

    Oncologist, Vol. 18, Núm. 8, pp. 917-923

  2. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: Efficacy and safety data according to liver function

    Clinical and Translational Oncology, Vol. 15, Núm. 2, pp. 146-153

  3. Targeted therapies in older patients with metastatic colorectal cancer

    Management of Colorectal Cancers in Older People (Springer-Verlag London Ltd), pp. 141-159